Pfizer’s stock jumped Tuesday after CEO Albert Bourla and President Donald Trump announced a deal to lower U.S. drug prices and invest $70 billion in domestic manufacturing, while shielding the company from tariffs. Critics blasted the lack of transparency, with watchdog groups filing FOIA requests to uncover the agreement’s undisclosed terms.